Gefitinib resistance of cancer cells correlated with TM4SF5-mediated epithelial-mesenchymal transition.


Although cancers can be initially treated with the epidermal growth factor receptor (EGFR) inhibitor, gefitinib, continued gefitinib therapy does not benefit the survival of patients due to acquired resistance through EGFR mutations, c-MET amplification, or epithelial-mesenchymal transition (EMT). It is of further interest to determine whether mesenchymal… (More)
DOI: 10.1016/j.bbamcr.2011.11.017


4 Figures and Tables